Spontanuous Demand For Meningococcal B Vaccination: Effects On Appropriateness And Timing

References

• Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17. doi:10.1186/1478-7954-11-17. PMID:24016339.
   PubMed Web of Science ®Google Scholar
• Pelton SI. The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines. J Adolesc Health. 2016;S3–S11. doi:10.1016/j.jadohealth.2016.04.012. PMID:27449148.
   PubMed Web of Science ®Google Scholar
• European Center for Disease prevention and Control. Annual epidemiological report 2016- Invasive meningococcal disease. Stockholm: ECDC;2016.: http://ecdc.europa.eu/en/healthtopics/meningococcal/Pages/Annual-epidemiological-report-2016.aspx ( accessed june2017)
   Google Scholar
• Sridhar S, Greenwood B, Head C, Plotkin SA, Sáfadi MA, Saha S, Taha MK, Tomori O, Gessner BD. Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis. 2015;15(11):1334–46. doi:10.1016/S1473-3099(15)00217-0. PMID:26453240.
   PubMed Web of Science ®Google Scholar
• Tirani M, Meregaglia M, Melegaro A. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme. PLoS One. 2015;10(4).e0123383. doi:10.1371/journal.pone.0123383. PMID:25874805.
   PubMed Web of Science ®Google Scholar
• Rota MC, Bella A, D'Angelo F, Fabiani M, Giambi C, et al. Vaccinazione anti-meningococcoB: dati ed evidenze disponibili per l'introduzione in nuovi nati e negli adolescenti (giugno 2014) Rapporti ISTISAN 15/12. http://old.iss.it/binary/publ/cont/15_12.pdf
   Google Scholar
• Azzari C, Canessa C, Lippi F, Moriondo M, Indolfi G, Nieddu F, Martini M, de Martino M, Castiglia P, Baldo V, et al. Distribution of invasive meningococcal B disease in Italian pediatric population: implications for vaccination timing. Vaccine. 2014;32(10):1187–91. doi:10.1016/j.vaccine.2013.09.055. PMID:24120548.
   PubMed Web of Science ®Google Scholar
• Stefanelli P, Fazio C, Neri A, Boros S, Renna G, Pompa MG; National Surveillance System Collaborative Centers Changing epidemiology of Infant Meningococcal Disease after the introduction of meningococcal serogroup C vaccine in Italy, 2006-2014. Vaccine. 2015;33(31):3678–81. doi:10.1016/j.vaccine.2015.06.032. PMID:26087297.
   PubMedGoogle Scholar
• Istituto Superiore di Sanità (ISS). Dati di sorveglianza delle malattie batteriche invasive aggiornati al 3 aprile 2017 http://www.iss.it/binary/mabi/cont/Report_MBI_20170403_finale.pd
   Google Scholar
• Neri A, Pezzotti P, Fazio C, Vacca P, D'Ancona FP, Caporali MG, Stefanelli P. Epidemiological and Molecular Characterization of Invasive Meningococcal Disease in Italy, 2008/09-2012/13. PLoS One. 2015;10(10):e0139376. doi:10.1371/journal.pone.0139376. PMID:26445461.
   PubMed Web of Science ®Google Scholar
• Bollettino Ufficiale Regione Abruzzo (BURA) bura.regione.abruzzo.it/singolodoc.aspx?link = 2016/Ordinario_44_1.html.
   Google Scholar
• Piano Nazionale Prevenzione Vaccinale –PNPV 2017–2019. Disponibile su: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf
   Google Scholar
• Ministero della salute: dati coperture vaccinali per singolo antigene http://www.salute.gov.it/portale/documentazione/p6_2_8_3_1.jsp?lingua=italiano&id = 20
   Google Scholar
• Ministero della salute: dati coperture vaccinali per HPV http://www.salute.gov.it/portale/temi/p2_6.jsp?id=811&area=Malattie%20infettive&menu=vaccinazioni.
   Google Scholar
• Morrone T, Napolitano F, Albano L, Di Giuseppe G. Meningococcal serogroup B vaccine: knowledge and acceptability among parents in Italy. Hum Vaccin Immunother. 2017;13(8):1921–7. doi:10.1080/21645515.2017.1313940. PMID:28441109.
   PubMed Web of Science ®Google Scholar
• Vezzosi L, Santagati G, Angelillo IF. Knowledge, attitudes, and behaviors of parents towards varicella and its vaccination. BMC Infect Dis. 2017;17(1):172. doi:10.1186/s12879-017-2247-6. PMID:28241788.
   PubMed Web of Science ®Google Scholar
• Bianco A, Pileggi C, Iozzo F, Nobile CG, Pavia M. Vaccination against human papilloma virus infection in male adolescents: knowledge, attitudes, and acceptability among parents in Italy. Hum Vaccin Immunother. 2014;10(9):2536–42. doi:10.4161/21645515.2014.969614. PMID:25483471.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, Toneatto D, Graña G, Wang H, Clemens R, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617–24. doi:10.1016/S0140-6736(11)61713-3. PMID:22260988.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O'Ryan M, Valenzuela MT, Prado V, Vergara RF, Muñoz A, Toneatto D, Graña G, Wang H, Dull PM, et al. Persistence of antibodies in adolescents 18–24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother. 2013;9(11):2304–10. doi:10.4161/hv.25505. PMID:23811804.
   PubMed Web of Science ®Google Scholar
• Hong E, Terrade A, Taha MK. Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine. Hum Vaccin Immunother. 2017;13(3):645–8. doi:10.1080/21645515.2016.1241358. PMID:27808594.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Prymula R, Merrall E, Kohl I, Toneatto D, Dull PM. Meningococcal serogroup B vaccine (4MenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children. Vaccine. 2015;33(32):3850–8. doi:10.1016/j.vaccine.2015.06.079. PMID:26141011.
   PubMed Web of Science ®Google Scholar
• Snape MD, Saroey P, John TM, Robinson H, Kelly S, Gossger N, Yu LM, Wang H, Toneatto D, Dull PM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ. 2013;85(15):E715–24. doi:10.1503/cmaj.130257.
   Google Scholar
• McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Yu LM, Toneatto D, D'Agostino D, Dull PM, Pollard AJ, et al. Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. CMAJ. 2015;187(7):E215–23. doi:10.1503/cmaj.141200. PMID:25802309.
   PubMed Web of Science ®Google Scholar
• Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, et al. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial. Vaccine. 2017;35(2):395–402. doi:10.1016/j.vaccine.2016.11.009. PMID:27914744.
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Sell T, Iro MA, Snape MD, Voysey M, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, et al. Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddeler schedules. CMAJ. 2017;189(41):E1276–E1285. doi:10.1503/cmaj.161288. PMID:29038320
   PubMed Web of Science ®Google Scholar
• Mameli C, Faccini M, Mazzali C, Picca M, Colella G, Duca PG, Zuccotti GV. Acceptability of meningococcal serogroup B vaccine among parents and health care workers in Italy: A survey. Hum Vaccin Immunother. 2014;10(10):3004–10. doi:10.4161/21645515.2014.971602. PMID:25483638.
   PubMed Web of Science ®Google Scholar
• Anello P, Cestari L, Baldovin T, Simonato L, Frasca G, Caranci N, Grazia Pascucci M, Valent F, Canova C. Socioeconomic factors influencing childhood vaccination in two northern Italian regions. Vaccine. 2017;35(36):4673–80. doi:10.1016/j.vaccine.2017.07.058. PMID:28757057.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Choe YJ, Hong YJ, Kim KH, Park SE, Kim YK, Oh CE, Lee H, Song H, Bock H, Casula D, Bhusal C, Arora AK. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea–A randomised trial. Vaccine. 2016;34(9):1180–6. doi:10.1016/j.vaccine.2016.01.033. PMID:26826544.
   PubMed Web of Science ®Google Scholar
• Langley JM, MacDougall DM, Halperin BA, Swain A, Halperin SA, Top KA, McNeil SA, MacKinnon-Cameron D, Marty K, De Serres G, Dubé E, Bettinger JA. Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study. Vaccine. 2016;34(34):4046–9. doi:10.1016/j.vaccine.2016.06.025. PMID:27302338.
   PubMed Web of Science ®Google Scholar
• Hambidge SJ, Newcomer SR, Narwaney KJ, Glanz JM, Daley MF, Xu S, Shoup JA, Rowhani-Rahbar A, Klein NP, Lee GM, et al. Timely versus delayed early childhood vaccination and seizures. Pediatrics. 2014;133(6):e1492–9. doi:10.1542/peds.2013-3429. PMID:24843064.
   PubMed Web of Science ®Google Scholar
• Rowhani-Rahbar A, Fireman B, Lewis E, Nordin J, Naleway A, Jacobsen SJ, Jackson LA, Tse A, Belongia EA, Hambidge SJ, et al. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr. 2013;167(12):1111–7. doi:10.1001/jamapediatrics.2013.2745. PMID:24126936.
   PubMed Web of Science ®Google Scholar
• Muta H, Nagai T, Ito Y, Ihara T, Nakayama T. Effect of age on the incidence of aseptic meningitis following immunization with monovalent mumps vaccine. Vaccine. 2015;33(45):6049–53. doi:10.1016/j.vaccine.2015.09.068. PMID:26431987.
   PubMed Web of Science ®Google Scholar
• Tabacchi G, Costantino C, Napoli G, Marchese V, Cracchiolo M, Casuccio A, Vitale F, The Esculapio Working Group. Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-analysis. Hum Vaccin Immunother. 2016;12(7):1909–23. PMID:27163657.
   PubMed Web of Science ®Google Scholar
• My C, Danchin M, Willaby HW, Pemberton S, Leask J Parental attitudes, beliefs, behaviours and concerns towards childhood vaccinations in Australia: A national online survey. Aust Fam Physician. 2017;46(3):145–51. PMID:28260278.
   PubMed Web of Science ®Google Scholar
• Salmon DA, Sotir MJ, Pan WK, Berg JL, Saad BO, Shannon S, Hopfensperger DJ, Davis JP, Halsey NA. Parental vaccine refusal in Wisconsin: a case-control study. WMJ. 2009;108(1):17–23. PMID:19326630.
   PubMedGoogle Scholar
• Jones AM, Omer SB, Bednarczyk RA, Halsey NA, Moulton LH, Salmon DA. Parents' source of vaccine information and impact on vaccine attitudes, beliefs, and non medicale xemptions. Adv Prev Med. 2012;2012:932741. doi:10.1155/2012/932741. PMID:23082253.
   PubMedGoogle Scholar
• Marshall HS, Chen G, Clarke M, Ratcliffe J. Adolescent, parent and societal preferences and willingness to pay for meningococcal B vaccine: A Discrete Choice Experiment. Vaccine. 2016;34(5):671–7. doi:10.1016/j.vaccine.2015.11.075. PMID:26740249.
   PubMed Web of Science ®Google Scholar
• Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GP, Postma MJ Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence. Hum Vaccin Immunother. 2013;9(5):1129–38. doi:10.4161/hv.23888. PMID:23406816
   PubMed Web of Science ®Google Scholar
• Lecocq H, Parent du Châtelet I, Taha MK, Lévy-Bruhl D, Dervaux B. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup Bmeningococcal disease in France. Vaccine. 2016;34(19):2240–50. doi:10.1016/j.vaccine.2016.03.020. PMID:27002504.
   PubMed Web of Science ®Google Scholar
• Tu HA, Deeks SL, Morris SK, Strifler L, Crowcroft N, Jamieson FB, Kwong JC, Coyte PC, Krahn M, Sander B. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Vaccine. 2014;32(42):5436–46. doi:10.1016/j.vaccine.2014.07.096. PMID:25131732.
   PubMed Web of Science ®Google Scholar
• Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact. Vaccine. 2013;31(23):2638–46. doi:10.1016/j.vaccine.2013.03.034. PMID:23566946.
   PubMed Web of Science ®Google Scholar
• Questionario vaccinazioni pediatriche – Regione Veneto https://prevenzione.aulss9.veneto.it/docs/RicercheScelteVaccinali/AllegatiReport/All_16_Questionario_Genitori_Cartaceo_web.pdf
   Google Scholar